Alpha Cognition Inc. (NASDAQ: ACOG) announced results from its BEACON real-world study evaluating ZUNVEYL in long-term care residents with mild to moderate Alzheimer's disease. The retrospective observational study involved 21 investigators treating 162 patients who received ZUNVEYL for 3 to 12 months.

According to provider assessments, 92% of patients showed cognitive improvement following ZUNVEYL initiation. Providers reported improvement in neuropsychiatric symptoms in 93% of patients and delayed initiation or discontinuation of psychotropic medications in 80% of patients. Activities of daily living improved in 71% of patients, while sleep-related outcomes improved in 72% of patients.

The study examined patients who had received prior acetylcholinesterase inhibitor treatment or discontinued such therapies due to limited efficacy or tolerability issues. Providers reported a favorable overall treatment experience in 98% of patients receiving ZUNVEYL.

The company emphasized that BEACON was a retrospective observational study without a randomized control group, meaning the reported observations cannot establish causality and should not be interpreted as evidence that ZUNVEYL caused the reported outcomes.

"Long-term care patients with Alzheimer's disease remain underrepresented in traditional clinical datasets despite representing a significant and clinically complex treatment population," said Michael McFadden, Chief Executive Officer of Alpha Cognition.

ZUNVEYL is a cholinesterase inhibitor approved for treating mild to moderate dementia of the Alzheimer's type in adults. The drug was designed with a metabolic profile that reduces gastrointestinal exposure to galantamine compared to conventional oral galantamine formulations.

Alpha Cognition is a biopharmaceutical company developing treatments for neurodegenerative diseases including Alzheimer's disease and cognitive impairment with mild traumatic brain injury.